The EFEMP1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the EFEMP1 gene has been disrupted. This product provides a genetically heterogeneous pool of HT29 cells carrying targeted loss-of-function mutations at the EFEMP1 locus, enabling functional studies without the limitations of clonal isolation. The polyclonal format captures population-level variation, ensuring robust representation of knockout effects while mitigating clonal artifacts.
The HT29 cell line is a well-characterized human colorectal adenocarcinoma model with epithelial morphology, originally isolated from a primary tumor. HT29 cells exhibit hallmark features of colorectal cancer, including aberrant activation of Wnt/??-catenin signaling due to truncating APC mutations, and are widely employed in cancer biology, drug screening, and intestinal physiology research. Their capacity for differentiation under specific culture conditions adds versatility for investigating cell fate and tumor microenvironment interactions.
EFEMP1 encodes fibulin-3, an extracellular matrix glycoprotein that functions as a tumor suppressor in multiple cancers. In the colorectal context, fibulin-3 antagonizes Wnt/??-catenin signaling, likely by interfering with ligand?Creceptor engagement, leading to reduced ??-catenin stabilization and diminished TCF/LEF transcriptional activity. Consequently, expression of oncogenic targets such as MYC and CCND1 is repressed. Fibulin-3 also inhibits angiogenesis by downregulating VEGF and suppressing the activities of matrix metalloproteinases MMP-2 and MMP-9. Upstream, EFEMP1 is silenced by promoter hypermethylation and is regulated by TGF-??1, SP1, and hypoxia via HIF-1??; it interacts with integrins, EGFR, fibronectin, collagen, and TIMP-3.
In HT29 cells, where Wnt/??-catenin signaling is constitutively active due to APC deficiency, disruption of EFEMP1 removes a critical tumor-suppressive constraint, enhancing oncogenic transcription and angiogenic potential. The knockout cells are expected to display elevated ??-catenin activity, increased VEGF and MMP levels, and heightened invasive capacity, recapitulating aspects of advanced colorectal carcinoma. This model therefore enables precise dissection of fibulin-3??s role in tumor suppression and provides a platform for exploring therapeutic strategies targeting Wnt or angiogenic pathways in a relevant cancer background.
These polyclonal knockout cells are applicable to a diverse array of colorectal cancer research areas, including tumor microenvironment studies, angiogenesis, drug resistance, and extracellular matrix dynamics. Typical assays include immunoblotting and RT?qPCR for EFEMP1 and pathway components, Wnt reporter assays, Matrigel invasion, tube formation assays with conditioned medium, and co?immunoprecipitation of ??-catenin. They can also be used in xenograft models to assess metastatic behavior and as a control for EFEMP1-dependent processes. For further information, contact Ascent Research.
